Physician profile
Efrain O Dickson
NPI 1235164526
$584.70
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2021: $88.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $117.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.22 | 2019 | |
| Abbott Laboratories | $88.66 | 2021 | |
| Amarin Pharma, INC. | $83.41 | 2019 | |
| Lilly USA, LLC | $72.51 | 2019 | |
| Glaxosmithkline, LLC. | $58.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.10 | 2019 | |
| Amgen INC. | $17.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.59 | 2019 | |
| Radius Health, INC. | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.